Phase II trial of paclitaxel and topotecan with granulocyte colony- stimulating factor support in stage IV breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2032-2037

  Fleming, Gini F ^a   Kugler, John W ^a   Hoffman, Philip C ^a   Ansari, Rafat ^a   Bitran, Jacob D ^a   Klepsch, Amy ^a   Malone, Donna ^a   Fasanmade, Adedigbo A ^a   Ratain, Mark J ^a   Vokes, Everett E ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEVER; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0031801498     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2032     Document Type: Article

References (31)

1. Holmes, FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
3. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
4. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily treated breast cancer: A National Cancer Institute treatment referral center trial. J Clin Oncol 13:2056-2065, 1995
5. Hortobagyi GN, Ibrahim N: Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol 23:53-57, 1996 (suppl 1)
6. Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
7. Ahmann DL, Sehaid DJ, Bisel HF, et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 5:1928-1932, 1987
8. Simers RJ, Gebski V, Coates AS, et al: Quality of life (QOL) with single agent mitozantrone or combination chemotherapy (CMFVP) for advanced breast cancer: A randomized trial. Proc Am Soc Clin Oncol 12:73, 1994 (abstr)
9. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy tor patients with metastatic breast cancer. J Clin Oncol 5:1377-1387, 1988
10. Chou T-C, Motzer RT, Tong Y, et al: Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
11. Burris HA, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816-1820, 1992
12. Burris HA, Rothenberg ML, Kuhn JG, et al: Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19:663-669, 1992
13. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well tolerated regimen. J Clin Oncol 12:553-559, 1994
14. Chang AY, Garrow G, Boros L, et al: Clinical and laboratory studies of topotecan in breast cancer. Proc Am Soc Clin Oncol 14:105, 1995 (abstr)
15. Lilenbaum RC, Ratain MJ, Miller AA, et al: Phase I study of paclitaxel and topotecan in patients with advanced tumors: A Cancer and Leukemia Group B study. J Clin Oncol 13:2230-2237, 1995
16. Huizing MT, Vermorken JB, Rosing H, et al: Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial. Ann Oncol 6:699-704, 1995
17. Beijnen JH, Smith BR, Keijer WJ, et al: High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 8:789-794, 1990
18. Minami H, Beijnen JH, Verweij J, et al: Limited sampling model for area under the concentration time curve of topotecan. Clin Cancer Res 2:43-46, 1996
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
20. p. Technometrics 15:661-676, 1973
21. Goldschmidt E, Bonneterre J, Fumoleau P, et al: A phase II study of topotecan on a daily x 5 schedule as second-line single agent therapy in patients with advanced breast cancer. Proc Am Soc Clin Oncol 16:171a, 1997 (abstr)
22. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
23. O'Reilly S, Fleming GF, Baker SD, et al: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study. J Clin Oncol 15:177-186, 1997
24. Kaufmann SH, Peereboom D, Buckwalter CA, et al: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741, 1996
25. Jensen PB, Holm B, Sorensen M, et al: In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, Taxol, topotecan and gemcitabine. Br J Cancer 75:869-877, 1997
26. Jett JR, Day R, Levitt M, et al: Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 18:13, 1997 (suppl 1; abstr)
27. Miller AA, Lilenbaum RC, Lynch TJ, et al: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 14:1964-1969, 1996 (letter)
28. O'Reilly S, Rowinsky EK, Slichenmyer W, et al: Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062-3073, 1996
29. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
30. Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCCTG, and ECOG study. Proc Am Soc Clin Oncol 15:280, 1996 (abstr)
31. Rowinsky EK, Mackey MK, Goodman SN: Metaanalysis of paclitaxel (P) dose-response and dose-intensity (DI) in recurrent or refractory ovarian cancer (OC). Proc Am Soc Clin Oncol 15:284, 1996 (abstr)